This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 25% and 28.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
3 Medical Stocks Creating Wealth Despite Macro Challenges
by Indrajit Bandyopadhyay
Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.
TransMedics (TMDX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 37.50% and 35.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 5.48% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights TransMedics, PROCEPT BioRobotics and Sensus Healthcare
by Zacks Equity Research
TransMedics, PROCEPT BioRobotics and Sensus Healthcare are part of the Zacks top Analyst Blog Highlights.
3 Resilient Medical Stocks to Watch as Rate Hikes Continue
by Indrajit Bandyopadhyay
Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -28.13% and 26.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -8.57% and 55.34%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Soars 9.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -46.88% and -30.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
by Zacks Equity Research
TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -44.44% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -3.57% and 1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?